Table 1 Summary of cell-surface molecules for targeted therapy and ongoing clinical trials in NKTCL patients
From: Novel target and treatment agents for natural killer/T-cell lymphoma
Agent | Target | Trial ID | Patient number (evaluable /estimate) | Study phase | Combined agents | Indication | Results for NKTCL | References | |
|---|---|---|---|---|---|---|---|---|---|
Cell-surface-targeted antibodies | Daratumumab | CD38 | NCT02927925 | 32 | 2 | / | r/r NKTCL | ORR:25%, CR:0% 4-m PFS:13% 6-m OS:42.9% | [16] |
| Â | Isatuximab | CD38 | NCT04763616 | 37 | 2 | Cemiplimab | r/r NKTCL | / | / |
| Â | Basiliximab | CD25 | NCT04337593 | 30 | 2 | Pegaspargase | r/r NKTCL | / | / |
| Â | Alemtuzumab | CD52 | NCT00069238 | 31 | 2 | EPOCH | Untreated T and NK-cell lymphoma | / | / |
| Â | Brentuximab vedotin | CD30 | NCT02280785 | 33 (7 NKTCL) | 2 | / | r/r CD30-expressing NHL | ORR:29% | [22] |
| Â | Brentuximab vedotin | CD30 | NCT03246750 | 36 | 1/2 | MAD | Newly diagnosed ENKTL | / | / |
CAR-T Therapy | CD30.CAR-T | CD30 | NCT04526834 | 21 | 1 | Â | r/r CD30 positive NHL | / | / |
| Â | CD30.CAR-T | CD30 | NCT03049449 | 26 | 1 | Cyclophosphamide Fludarabine | CD30 expressing lymphomas | / | / |
| Â | CD30.CAR-EBVSTs | CD30 | NCT04288726 | 18 | 1 | Â | r/r CD30 positive NHL | / | / |
EBV targeted CTL | Baltaleucel-T | EBV antigens | NCT01948180 | 15 | 2 | Â | Advanced ENKTL | Salvage cohort: ORR:50% CR:30% | [73] |
| Â | VT-EBV-N | LMP | NCT03671850 | 48 | 2 | Â | EBV positive NKTCL | Â | Â |